Contract with Alpha Biologics

Synairgen plc
12 November 2007


PRESS RELEASE                                                                  


                                  SYNAIRGEN PLC
                         ('Synairgen' or the 'Company')


               Contract Signed To Advance Growth Factor Programme


Synairgen, the company developing novel therapies for asthma and COPD, today
announces that it has selected Alpha Biologics in connection with the
advancement of its growth factor drug development programme.


Alpha Biologics, Cambridge, UK, is an independent contract biomanufacturing
organisation offering FDA/EMEA cGMP compliant services to the worldwide
pharmaceutical and biotechnology industry. Synairgen is working with Alpha
Biologics to develop a scaleable manufacturing process for Synairgen's optimised
growth factor to support pre-clinical and clinical development.


Richard Marsden, Synairgen's Managing Director, said, 'We have significant
confidence in our growth factor drug development programme for asthma to restore
barrier function in patients. Initiating the development of a scaleable
manufacturing process is another significant milestone for the programme.'


'We are pleased to be associated with such an exciting programme from a company
at the forefront in their field', said Alpha's CEO, Mr Simon Saxby.


                                     -Ends-


For further information, please contact:

Synairgen                                            Tel: + 44 (0) 2380 512 800
Richard Marsden, Managing Director
John Ward, Finance Director

Alpha Biologics                                      Tel: + 44 (0) 1223 496 070
Jon Mowles, Commercial Director

The Hogarth Partnership (Synairgen Media Enquiries)  Tel: + 44 (0) 20 7357 9477
Melanie Toyne-Sewell





Notes to Editors


About Synairgen

Synairgen is a drug discovery company founded by Professors Stephen Holgate,
Donna Davies and Ratko Djukanovic, focused on identifying and out-licensing new
pharmaceutical products which address the underlying causes of asthma and
chronic obstructive pulmonary disease. Synairgen is listed on AIM (LSE: SNG).

For more information about Synairgen, please see www.synairgen.com.


About Synairgen's Growth Factor Programme

Synairgen's researchers have found that the cells which line the airways (the
epithelium) of asthmatics do not form a robust barrier. This defect in barrier
function may be a key contributor to asthma susceptibility enabling known
triggers of asthma, such as allergens, pollutants and viruses, to penetrate
through the epithelium to the underlying tissue. Using asthmatic epithelial
cells from its biobank of human tissue, Synairgen has developed a modified
growth factor that can restore barrier function.


About Alpha Biologics

Alpha Biologics is an independent contract biomanufacturing organisation
offering FDA/EMEA cGMP compliant services to the worldwide pharmaceutical and
biotechnology industry. Initial process development is undertaken in Cambridge,
England, before being transferred to scale up facilities for final process
technology transfer and manufacturing of biologics drugs for pre-clinical and
clinical trials. The company is headquartered in Malaysia. For more information,
please see www.alphabiologics.com.





                      This information is provided by RNS
            The company news service from the London Stock Exchange